CDC Health Advisory about Increases in Availability of Cannabis Products Containing Delta-8 THC and Reported Cases of Adverse Events

Published: 09/14/2021

  • Centers for Disease Control and Prevention
Relevant To:
  • Urgent Care,
  • Behavioral Health - Outpatient,
  • Medical Office,
  • Critical Access Hospitals,
  • Hospitals,
  • Community Mental Health Centers,
  • Ambulatory Care,
  • Clinical Lab,
  • Behavioral Health - Inpatient,
  • Rural Health Clinics

The U.S. Centers for Disease Control and Prevention (CDC) has issued a new Health Advisory to raise awareness about the increased availability of cannabis products containing delta-8 tetrahydrocannabinol and the potential for adverse events due to insufficient labeling of products containing THC and cannabidiol (CBD).

The cannabis plant contains more than 100 cannabinoids, including delta-9 tetrahydrocanna (THC), which is psychoactive and causes a “high”. CBD is another active cannabinoid fou

Sign Up for Free Trial